Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447873 | PMC |
| http://dx.doi.org/10.1016/S2468-1253(21)00013-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Innovations in colorectal cancer treatment: trifluridine and tipiracil with bevacizumab for improved outcomes - a review.
Front Oncol
July 2024
Internal Medicine, Jinnah Sindh Medical University (JSMU), Karachi, Pakistan.
Colorectal cancer ranks second in cancer-related deaths throughout the world. At the time of diagnosis, at least 20% of the patients with CRC had already developed metastases. Treating and effectively managing metastatic colorectal cancer remains an unsolved task for the health sector.
View Article and Find Full Text PDFRamucirumab Beyond Disease Progression After Paclitaxel Plus Ramucirumab in Gastric Cancer: A Phase II Trial.
Anticancer Res
July 2024
Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Background/aim: Irinotecan monotherapy was the most widely used third-line chemotherapy for unresectable advanced or recurrent gastric cancer in Japan until the approval of nivolumab in September 2017 and trifluridine/tipiracil in August 2019. The benefit of continuing ramucirumab with irinotecan, an anti-VEGFR-2 monoclonal antibody, after the failure of paclitaxel plus ramucirumab (PTX+RAM) as second-line chemotherapy, has been under debate.
Patients And Methods: A single-center phase II study was conducted in patients with unresectable advanced or recurrent gastric cancer previously treated with fluoropyrimidines and platinum, who received PTX+RAM as second-line therapy and irinotecan plus ramucirumab (IRI+RAM) as third-line therapy after treatment failure (UMIN000022956).
Trifluridine/tipiracil with and without ramucirumab for advanced gastric cancer: a comparative observational study.
Sci Rep
June 2024
Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan.
Article Synopsis
- * Results showed the combination therapy resulted in higher objective response rates (25.8% vs. 5.0%) and longer median progression-free survival (2.9 months vs. 1.8 months) compared to FTD/TPI monotherapy.
- * While the combination therapy led to a higher rate of febrile neutropenia (13.8% vs. 2.9%), it was generally well-tolerated, suggesting it could provide clinical benefits
Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer.
Nagoya J Med Sci
February 2024
Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
In Japan, systemic chemotherapy is the standard treatment for unresectable, advanced, or recurrent gastric cancer. However, numerous patients with gastric cancer do not receive late-line treatment because of the rapid progression of gastric cancer. Additionally, late-line treatments, such as nivolumab, trifluridine tipiracil (FTD/TPI), or irinotecan, have limited effects on improving clinical symptoms and delaying the onset of symptoms associated with cancer progression.
View Article and Find Full Text PDFChronological improvement of survival in patients with advanced gastric cancer over 15 years.
Ther Adv Med Oncol
February 2024
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Background: Recent trials have reported a median overall survival (OS) of 11-17 months in patients with advanced gastric cancer (AGC). However, it is unclear how recently approved drugs contribute to patient prognosis.
Objectives: We aimed to evaluate the characteristics and survival in patients with AGC over the past 15 years.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!